Tempest Therapeutics
TPST
18 hedge funds and large institutions have $6.42M invested in Tempest Therapeutics in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 8 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
45% more capital invested
Capital invested by funds: $4.42M → $6.42M (+$2M)
24.64% more ownership
Funds ownership: 1.01% → 25.65% (+25%)
22% less funds holding
Funds holding: 23 → 18 (-5)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
51% less call options, than puts
Call options by funds: $89K | Put options by funds: $180K
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.97M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$988K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$794K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.97K |
| 5 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$1.78K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$97.2K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$73.4K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$62.6K |
| 4 |
DC
Davenport & Co
Richmond,
Virginia
|
-$36.9K |
| 5 |
State Street
Boston,
Massachusetts
|
-$30.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| – | -$57 | -6 | Closed |
|
TPST Hedge Fund Activity: Q2 2025 in Review
18 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q2 2025, worth a combined $6.42M — up 45% from $4.42M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of TPST and 3 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 4 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.97M. The largest seller was UBS Group, cutting an estimated $97.2K.
- 18 institutional investors held Tempest Therapeutics (TPST) as of Q2 2025, down from 23 in Q1 2025.
- Funds reported $6.42M of Tempest Therapeutics stock for Q2 2025, up 45% quarter-over-quarter.
- 3 funds opened new Tempest Therapeutics positions in Q2 2025 and 8 closed out, a net change of -5 holders.
- The largest Tempest Therapeutics buyer in Q2 2025 was Sabby Management, an estimated $1.97M added.
- The largest Tempest Therapeutics seller in Q2 2025 was UBS Group, an estimated $97.2K sold.
Based on aggregated 13F filings for Q2 2025.